Navigation Links
PET scans confirm effectiveness of estrogen-blocking drugs in breast cancer patients
Date:8/18/2011

SEATTLE For the first time, researchers at Seattle Cancer Care Alliance have demonstrated the feasibility of using serial positron emission tomography (PET) scans, using a special estrogen-containing isotope, to confirm the relative effectiveness of estrogen-blocking and estrogen-depleting therapy in patients with metastatic breast cancer. The results of the research are published online in Clinical Cancer Research.

The PET scans, taken before, during and after hormonal therapy, confirmed the superior effectiveness of estrogen-receptor-blocking drugs such as tamoxifen and fulvestrant over estrogen-depleting therapies such as aromatase inhibitors in blocking the estrogen receptor in cancer cells. The study also confirmed that tamoxifen is superior to fulvestrant in blocking estrogen.

While the results were expected they had never before been proven, according to corresponding author Hannah Linden, M.D., a breast oncologist at SCCA and an associate professor of Medicine at the University of Washington School of Medicine.

Linden and colleagues measured regional estrogen-receptor blocking and binding by using PET scans with 18F-flouroestradiol (FES), a trace amount of estrogen in isotope form, prior to and during treatment with aromatase inhibitors, tamoxifen and fulvestrant in a series of 30 patients whose breast cancer had spread to the bones. Tumor FES uptake declined more markedly in patients who took estrogen-receptor blockers compared to those who took estrogen-depleting aromatase inhibitors (an average decline of 54 percent versus 15 percent, respectively). Among the two estrogen-blocking drugs studied, the rate of complete tumor blockade was highest following use of tamoxifen versus fulvestrant.

"What we're suggesting in the paper -- that we couldn't fully test for before -- is if estrogen is incompletely blocked you're not getting a good outcome for the patient," Linden said.

"Our findings support the ability of FES PET to visualize the in vivo activity of endocrine therapy," the authors concluded. "This technology could be used early in drug development to measure effectiveness at the intended therapeutic targets, and to help refine selection and dosing for agents to move forward in drug development."

Additionally, pharmacodynamic imaging could provide clinicians with a promising tool for therapeutic selection and for predicting and evaluating response to estrogen-receptor-targeted therapy, Linden said.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Use of CT scans in emergency rooms increased 330 percent in 12 years
2. CT scans unleash a breakthrough in catching early stage lung cancer
3. More Evidence CT Scans Better at Detecting Lung Cancer
4. Lung cancer screening trial shows screening with CT scans reduces lung cancer deaths
5. Hospitalizing children with normal CT scans after blunt head trauma is not necessary
6. Brain Scans to Spot Alzheimers May Be Available This Year
7. Chronic Pot Smoking Affects Brain Chemistry, Scans Show
8. PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients
9. CT Heart Scans No Benefit to Patients Without Symptoms
10. Scans of Egyptian Mummies Show Heart Disease Was Ancient Malady
11. Large study finds CT scans are frequently unnecessary after head injury in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic ... . The forum section was recently revamped and upgraded to allow even more interaction ... use across the country. , According to the senior editor of Cosmetic Town, “We ...
(Date:4/28/2016)... ... ... In many parts of the world, contamination from human waste is a ... in underdeveloped parts of Africa where clean sources of food and water are scarce. ... will examine this global health issue and consider how it compares to other major ...
(Date:4/28/2016)... , ... April 28, 2016 ... ... provider of enterprise Data Center Infrastructure Management solutions, announces today the availability ... feature enhancements in the area of capacity management and optimization, providing new ...
(Date:4/28/2016)... Texas (PRWEB) , ... April 28, 2016 , ... Amada ... opened its newest office in San Antonio – its San Antonio West location. Prior ... years in medical device sales. The grand opening of Amada San Antonio West will ...
(Date:4/28/2016)... ... April 28, 2016 , ... Anzu®, ... announced a new Residency Education & Collaboration Platform for hospitals and medical ... and a host of collaboration tools designed to improve patient outcomes through ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
(Date:4/27/2016)... , April 27, 2016 ... accelerator (MR-linac) platform will be the focal point of ... of the European Society for Radiotherapy & Oncology, taking ... MR-linac integrates a state-of-the-art radiotherapy system and a high-field ... to clearly see the patient,s anatomy in real time. ...
(Date:4/27/2016)... , April 27, 2016 Shire ... Jeff Poulton , Chief Financial Officer, will present at ... Boston, MA on Wednesday, May 04, 2016, ... webcast will be available on the Presentations and Webcasts section ... replay of the webcast will be available on this same ...
Breaking Medicine Technology: